Phase 4CompletedINTERVENTIONAL
Combined Active Treatment in Type 2 Diabetes With NASH
ClinicalTrials.gov · NCT04639414 · Registry updated: 2026-07-08
- Condition / research focus
- Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD)
- Sponsor
- German Diabetes Center
- Countries with listed sites
- Austria · Germany
- Registry dates and results
- Start: 2021-03-26. Completion: 2025-11-17 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector (drug) — also listed as: Jardiance(R), Ozempic(R)
- Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide (drug) — also listed as: Jardiance(R)
- Placebo matching empagliflozin and placebo pen injector matching semaglutide (drug) — also listed as: Control / Placebo
Where the study takes place — 26 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.